Maslov Leonid N, Popov Sergey V, Mukhomedzyanov Alexandr V, Derkachev Ivan A, Ryabov Vyacheslav V, Boshchenko Alla A, Prasad N Rajendra, Sufianova Galina Z, Khlestkina Maria S, Gareev Ilgiz
Cardiology Research Institute, Tomsk National Research Medical Center of the RAS, Tomsk, Russia.
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamilnadu, India.
Korean Circ J. 2022 Oct;52(10):737-754. doi: 10.4070/kcj.2022.0162.
Ischemic and reperfusion injuries of the heart underlie the pathogenesis of acute myocardial infarction (AMI) and sudden cardiac death. The mortality rate is still high and is 5-7% in patients with ST-segment elevation myocardial infarction. The review is devoted to pharmacological approaches to limitation of ischemic and reperfusion injuries of the heart. The article analyzes experimental evidence and the clinical data on the effects of P2Y receptor antagonists on the heart's tolerance to ischemia/reperfusion in animals with coronary artery occlusion and reperfusion and also in patients with AMI. Chronic administration of ticagrelor prevented adverse remodeling of the heart. There is evidence that sphingosine-1-phosphate is the molecule that mediates the infarct-reducing effect of P2Y receptor antagonists. It was discussed a role of adenosine in the cardioprotective effect of ticagrelor.
心脏的缺血和再灌注损伤是急性心肌梗死（AMI）和心源性猝死发病机制的基础。死亡率仍然很高，ST段抬高型心肌梗死患者的死亡率为5-7%。这篇综述致力于探讨限制心脏缺血和再灌注损伤的药理学方法。本文分析了关于P2Y受体拮抗剂对冠状动脉闭塞和再灌注动物以及AMI患者心脏对缺血/再灌注耐受性影响的实验证据和临床数据。长期服用替格瑞洛可预防心脏不良重塑。有证据表明，1-磷酸鞘氨醇是介导P2Y受体拮抗剂减少梗死作用的分子。文中还讨论了腺苷在替格瑞洛心脏保护作用中的作用。
